Stock Information

Markets
TSX20741.75+197.64
TSXV838.33+8.11
DOW34725.47+564.69
S&P 5004431.85+105.34
NASD13770.57+417.79
ASX6988.10+149.80
Commodities
Gold1792.11+0.81
Silver22.47+0.03
Copper4.33-0.10
Palladium2379.43+3.42
Platinum1014.00+3.00
Oil87.29+0.68
Heating Oil2.73+0.01
Natural Gas4.69+0.41
Currencies
BTCUSD37710.68-212.45
USDCAD1.2768+0.0014
USDEUR0.89700.0000
USDGBP0.7460+0.0003
USDAUD1.4306-0.0048
USDJPY115.25+0.06

Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine

-- Enrolled Patients in These Studies May Continue Receiving Study Medicine --

-- Studies Outside of Combination with Azacitidine Unaffected --

Keep reading... Show less

FDA Approves Veklury® for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression

-- Approval Based on Phase 3 Data Showing Veklury Significantly Reduced Risk of Hospitalization By 87% Compared with Placebo --

-- NIH Guidelines Recommend Veklury for the Treatment of Non-Hospitalized Patients at High Risk --

Keep reading... Show less

Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2021 financial results will be released on Tuesday, February 1, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's fourth quarter and full year 2021 financial results and will provide a business update.

A live webcast will be available on the investor relations page of http://investors.gilead.com and will be archived on www.gilead.com for one year.

Keep reading... Show less
×